TI Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis.
AN 87097896 EMBASE
DN 1987097896
TI Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis.
AU Need A.G.; Chatterton B.E.; Walker C.J.; et al.
CS Division of Clinical Chemistry, Institute of Medical and Veterinary Science, Adelaide, SA, Australia
SO Maturitas, (1986) 8/4 (275-280).
CODEN: MATUDK
CY Netherlands
DT Journal
FS 037 Drug Literature Index
020 Gerontology and Geriatrics
031 Arthritis and Rheumatism
030 Pharmacology
LA English
AB Most therapy for osteoporosis has been aimed at decreasing bone resorption and is capable of preventing further bone loss. Recently, anabolic steroids have been claimed to cause increased bone mass in osteoporosis, but the mechanism for this effect is not understood. In this study calcium, and calcium with calcitriol, caused a slowing of forearm bone mineral loss. Calcium and ovarian hormones, with or without calcitriol, caused a small non-significant rise in forearm mineral density, and nandrolone decanoate 50 mg intramuscularly, every 2 or 3 weeks caused a significant rise in forearm mineral density (+15.9 .+-. 2.4 mg/ml/yr and +13.7 .+-. 3.4 mg/ml/yr, respectively). The 3-weekly regime caused few side effects and is considered the optimal dose. The striking rise in bone density in patients in whom bone resorption was controlled before therapy, suggests that anabolic steroids can increase the bone formation rate.
RN (calcitriol) **32222-06-3**, 32511-63-0, 66772-14-3; (calcium) 7440-70-2; (nandrolone) 434-22-0; (nandrolone decanoate) 360-70-3; (norethisterone) **68-22-4**

TI Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.
AN 82050623 MEDLINE
DN 82050623 PubMed ID: 6795047
TI Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.
AU Christiansen C; Christensen M S; Rodbro P; Hagen C; Transbol I
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, (1981 Aug) 11 (4) 305-9. Journal code: 0245331. ISSN: 0014-2972.
CY ENGLAND: United Kingdom
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 198201
ED Entered STN: 19900316
Last Updated on STN: 19900316
Entered Medline: 19820109
AB Eighty-four normal women, 2.5--5 years after their natural menopause, participated in a controlled double-blind trial. The effect of various therapeutic regimens on postmenopausal bone mineral loss was measured by photonabsorptiometric determination of the bone mineral content of both forearms. The women were randomized into four treatment groups: 1,25-dihydroxycholecalciferol (1,25(OH)2D3) alone in a daily dose of 0.25 micrograms, oestrogens/gestagen alone or combined with 1,25(OH)2D3, and placebo. The groups treated with oestrogens/gestagen (without and with 1,25(OH)2D3) showed a similar increase in bone mineral content of about 1% during one year of treatment. In contrast, both the placebo group and the 1,25(OH)2D3 group demonstrated a decrease of 1.9% and 2.1%, respectively, within the same period of time. While 1,25(OH)2D3 did not alter the rate of bone loss, it caused the characteristic and pronounced increase in urinary calcium excretion (15%). It is concluded that 1,25 (OH)2D3 neither serves as an alternative nor as an additive to gonadal hormones in the prevention of postmenopausal osteoporosis.
RN **32222-06-3 (Calcitriol)**; 38673-38-0 (norethindrone acetate); 50-27-1 (Estriol); 50-28-2 (Estradiol); **68-22-4 (Norethindrone)**; 7440-70-2 (Calcium)

```
=> s 32222-06-3/rn
L1            1 32222-06-3/RN

=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   32222-06-3  REGISTRY
CN   9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta.,5Z,7E)-
       (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1,25-Dihydroxycholecalciferol
CN   1,25-Dihydroxyvitamin D
CN   1,25-Dihydroxyvitamin D3
CN   1.alpha.,25-(OH)2D3
CN   1.alpha.,25-Dihydroxycholecalciferol
CN   1.alpha.,25-Dihydroxyvitamin D3
CN   Calcijex
CN   Calcitriol
CN   Ro 21-5535
CN   Rocaltrol
CN   Silkis
CN   Soltriol
CN   Topitriol
CN   Toptriol
FS   STEREOSEARCH
DR   125338-24-1
MF   C27 H44 O3
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
       BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT,
       CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,
       DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
       MRCK*, NAPRALERT, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*,
       TOXCENTER, USAN, USPAT2, USPATFULL, VETU
         (*File contains numerically searchable property data)
     Other Sources:   EINECS**, WHO
         (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.
Double bond geometry as shown.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

          9398 REFERENCES IN FILE CA (1947 TO DATE)
           273 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
          9408 REFERENCES IN FILE CAPLUS (1947 TO DATE)
```

```
=> s norethindrone/cn
L2            1 NORETHINDRONE/CN

=> d l2

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   68-22-4  REGISTRY
CN   19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI)  (CA INDEX
     NAME)
OTHER CA INDEX NAMES:
CN   19-Nor-17.alpha.-pregn-4-en-20-yn-3-one, 17-hydroxy- (7CI, 8CI)
OTHER NAMES:
CN   (17.alpha.)-17-Hydroxy-19-Norpregn-4-en-20-yn-3-one
CN   17-Hydroxy-19-nor-17.alpha.-pregn-4-en-20 yn-3-one
CN   17.alpha.-Ethinyl-17.beta.-hydroxy-.DELTA.4-estren-3-one
CN   17.alpha.-Ethinyl-19-nortestosterone
CN   17.alpha.-Ethinylestr-4-en-17.beta.-ol-3-one
CN   17.alpha.-Ethynyl-17-hydroxy-4-estrene-3-one
CN   17.alpha.-Ethynyl-17-hydroxyest-4-en-3-one
CN   17.alpha.-Ethynyl-17-hydroxyestr-4-en-3-one
CN   17.alpha.-Ethynyl-17.beta.-hydroxy-19-norandrost-4-en-3-one
CN   17.alpha.-Ethynyl-17.beta.-hydroxyestr-4-en-3-one
CN   17.alpha.-Ethynyl-19-nor-androst-4-en-17.beta.-ol-3-one
CN   17.alpha.-Ethynyl-19-nortestosterone
CN   17.alpha.-Ethynyl-3-oxo-4-estren-17.beta.-ol
CN   17.beta.-Hydroxy-17.alpha.-ethynylestr-4-en-3-one
CN   19-Nor-17.alpha.-ethynyl-17.beta.-hydroxy-4-androsten-3-one
CN   19-Nor-17.alpha.-ethynylandrosten-17.beta.-ol-3-one
CN   19-Nor-17.alpha.-ethynyltestosterone
CN   19-Norandrost-4-en-3-one, 17.alpha.-ethynyl-17.beta.-hydroxy-
CN   19-Nortestosterone, 17-ethynyl-
CN   Anovule
CN   Conludaf
CN   Conludag
CN   Estr-4-ene-17.alpha.-ethynyl-17.beta.-ol-3-one
CN   Ethinylnortestosterone
CN   Ethynylnortestosterone
CN   Gestest
CN   Menzol
CN   Micronett
CN   Micronor
CN   Micronovum
CN   Mini-Pe
CN   Mini-pill
CN   Nor-QD
CN   Noralutin
CN   Norcolut
CN   Norethindrone
CN   Norethisteron
CN   Norethisterone
CN   Norethynodrone
CN   Norfor
CN   Norgestin
CN   Norluten
CN   Norlutin
CN   Norluton
CN   Normapause
CN   Norpregneninolone
CN   NSC 9564
CN   Primolut N
CN   Proluteasi
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
     DISPLAY
FS   STEREOSEARCH
```

MF C20 H26 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2149 REFERENCES IN FILE CA (1947 TO DATE)
63 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2149 REFERENCES IN FILE CAPLUS (1947 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.38	8.59

FILE 'CAPLUS' ENTERED AT 06:25:51 ON 23 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

TI Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis.
AN 87097896 EMBASE
DN 1987097896
TI Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis.
AU Need A.G.; Chatterton B.E.; Walker C.J.; et al.
CS Division of Clinical Chemistry, Institute of Medical and Veterinary Science, Adelaide, SA, Australia
SO Maturitas, (1986) 8/4 (275-280).
CODEN: MATUDK
CY Netherlands
DT Journal
FS 037 Drug Literature Index
020 Gerontology and Geriatrics
031 Arthritis and Rheumatism
030 Pharmacology
LA English
AB Most therapy for osteoporosis has been aimed at decreasing bone resorption and is capable of preventing further bone loss. Recently, anabolic steroids have been claimed to cause increased bone mass in osteoporosis, but the mechanism for this effect is not understood. In this study calcium, and calcium with calcitriol, caused a slowing of forearm bone mineral loss. Calcium and ovarian hormones, with or without calcitriol, caused a small non-significant rise in forearm mineral density, and nandrolone decanoate 50 mg intramuscularly, every 2 or 3 weeks caused a significant rise in forearm mineral density (+15.9 .+-. 2.4 mg/ml/yr and +13.7 .+-. 3.4 mg/ml/yr, respectively). The 3-weekly regime caused few side effects and is considered the optimal dose. The striking rise in bone density in patients in whom bone resorption was controlled before therapy, suggests that anabolic steroids can increase the bone formation rate.
RN (calcitriol) **32222-06-3**, 32511-63-0, 66772-14-3; (calcium) 7440-70-2; (nandrolone) 434-22-0; (nandrolone decanoate) 360-70-3; (norethisterone) **68-22-4**

TI Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.
AN 82050623 MEDLINE
DN 82050623 PubMed ID: 6795047
TI Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.
AU Christiansen C; Christensen M S; Rodbro P; Hagen C; Transbol I
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, (1981 Aug) 11 (4) 305-9. Journal code: 0245331. ISSN: 0014-2972.
CY ENGLAND: United Kingdom
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 198201
ED Entered STN: 19900316
Last Updated on STN: 19900316
Entered Medline: 19820109
AB Eighty-four normal women, 2.5--5 years after their natural menopause, participated in a controlled double-blind trial. The effect of various therapeutic regimens on postmenopausal bone mineral loss was measured by photonabsorptiometric determination of the bone mineral content of both forearms. The women were randomized into four treatment groups: 1,25-dihydroxycholecalciferol (1,25(OH)2D3) alone in a daily dose of 0.25 micrograms, oestrogens/gestagen alone or combined with 1,25(OH)2D3, and placebo. The groups treated with oestrogens/gestagen (without and with 1,25(OH)2D3) showed a similar increase in bone mineral content of about 1% during one year of treatment. In contrast, both the placebo group and the 1,25(OH)2D3 group demonstrated a decrease of 1.9% and 2.1%, respectively, within the same period of time. While 1,25(OH)2D3 did not alter the rate of bone loss, it caused the characteristic and pronounced increase in urinary calcium excretion (15%). It is concluded that 1,25 (OH)2D3 neither serves as an alternative nor as an additive to gonadal hormones in the prevention of postmenopausal osteoporosis.
RN **32222-06-3 (Calcitriol)**; 38673-38-0 (norethindrone acetate); 50-27-1 (Estriol); 50-28-2 (Estradiol); **68-22-4 (Norethindrone)**; 7440-70-2 (Calcium)